CurrentColorado Rocky Mountain Health PlansPolicy 2026T0080RR

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

Coverage policy for occipital nerve injections and ablation procedures (including occipital neuralgia and headache) for UnitedHealthcare Commercial and Individual Exchange plans; describes medically necessary and not medically necessary treatments and supporting evidence.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

Policy CodePolicy 2026T0080RR

Change TypeTemplate update / archival of prior versions

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain and document prior conservative therapy failure and, when applicable, a positive diagnostic or temporary trial response (commonly ≥50% pain reduction) to support prior authorization.

SourceLink

POLICY UPDATE CHANGES

Created shared policy version to support application to Oxford plan membership and archived previous policy versions.

mixedcoverage stance categories

CPT/HCPCS/ICDapplicable codes enumerated

multiple SRsevidence sources summarized

lowoverall long-term evidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

short-term benefit (GONB)

Coverage Criteria — Indications and Limitations

inv-01: Covered for malignancy-related head and neck pain

Covered when ALL of the following are met

Occipital procedures for malignancy-related pain: Injection of local anesthetics and/or steroids as greater occipital nerve blocks (GONBs) and occipital nerve ablation (destruction by neurolytic agent) are considered proven and medically necessary for treating pain due to malignancy involving the head and neck.

inv-02: Not medically necessary / Unproven for occipital neuralgia and headaches

The following are unproven and not medically necessary due to insufficient evidence of efficacy

Unproven treatments: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks; neurostimulation or electrical stimulation; occipital neurectomy; partial posterior intradural C1-C3 rhizotomy; radiofrequency ablation (thermal or pulsed) or denervation; rhizotomy of C1-C3 spinal dorsal roots; surgical decompression of second cervical nerve root and ganglion; surgical decompression of the greater occipital nerve.

These are listed specifically as unproven for diagnosing and/or treating occipital neuralgia or headaches including migraine and cervicogenic headaches.

inv-03: Covered with short-term benefit

Evidence-supported coverage considerations (short-term):

Short-term therapeutic effect: Randomized trials and meta-analyses show GONB can reduce headache intensity and frequency in the short term (hours to weeks) compared with baseline or placebo.timeframe: up to 6 weeks (varies by study)

Evidence quality often low; benefits appear short-term.

Indications with some supportive evidence: Migraine (episodic and chronic), cluster headache, cervicogenic headache, and post-dural puncture headache have studies reporting benefit after GONB.indication-specific evidence varies

Most RCTs and reviews show short-term benefit; long-term prevention evidence limited.

inv-04: Coverage restricted for long-term preventive therapy

Limitations and conditions where coverage is uncertain or requires additional justification:

Chronic preventive use: There is little to no high-quality evidence demonstrating benefit for chronic/long-term preventive use of GONB; authors call for larger, longer RCTs.long-term outcomes not established

Hayes and other reviews rate evidence as low/inconclusive.

inv-05: Surgery — not established

Surgical treatment for occipital neuralgia/cervicogenic headache:

Surgical interventions: Available surgical procedures (neurectomy, dorsal nerve root section, posterior rhizotomy, fusion, nerve release, neuroplasty) have insufficient high-quality evidence to conclude long-term effectiveness for occipital neuralgia or cervicogenic headache.evidence insufficient

No RCTs for neuroplasty; mixed low-quality literature for other surgical options.

inv-06: General coverage interpretation

Summary coverage stance derived from evidence in this section

Evidence-based coverage considerations: Coverage decisions should consider that the available evidence is insufficient to conclude long-term efficacy for many surgical procedures (neurectomy, decompression, neuroplasty, auriculotemporal and supratrochlear/SON decompression) and for some forms of RFA; conversely, some RCTs and systematic reviews report clinically meaningful improvements for migraine surgery and RFA in select populations.

Assess individual candidate selection, prior response to diagnostic blocks, and specialist evaluation.

inv-07: Selection criteria

Candidate selection criteria observed in the literature

Typical inclusion criteria used in studies: Patients often had failure of conservative therapies, a positive diagnostic nerve block response (e.g., ≥50% relief after GONB or C2 DRG block), and specialist (neurology or pain) evaluation prior to surgical or RFA intervention.>=50% diagnostic block relief

Documented positive response increases likelihood of procedural benefit.

inv-08: Reported efficacy

Outcomes reported in systematic reviews/meta-analyses

Reported benefit outcomes: Some meta-analyses report significant reductions in headache frequency, severity and MHI after migraine surgery (e.g., 13 fewer headache days/month at 1 year; reduction in severity by ~4/10; 38% elimination rate at 6–12 months). However, many included studies have high risk of bias and heterogeneity.

Clinical significance reported but further RCTs needed.

inv-09: Criteria for consideration of RFA / PRF and neurostimulation

Coverage considerations reflect the low-quality but potentially positive evidence; interventions are considered in selected, refractory cases when ALL of the following apply:

Selection and prior therapy: Patient has a specific refractory headache disorder (e.g., chronic migraine, cluster headache, occipital neuralgia) and has failed multiple adequate conservative and pharmacologic therapies as documented in the medical record.

Studies often required prior conservative therapy failure or refractory status.

Diagnostic/therapeutic trial response: When permanent implantable neurostimulation is contemplated, there is documented positive response to a temporary trial (commonly ≥50% reduction in pain or headache frequency).≥50% reduction commonly used in trials

Multiple studies and systematic reviews selected patients for permanent implantation based on a successful trial.

Targeted diagnostic block for RFA/PRF: For RFA or pulsed RFA targeting peripheral nerves or C2 DRG, a prior diagnostic block with clear positive response increases likelihood of benefit and is recommended to document target concordance.

inv-10: Evidence-based coverage considerations

Coverage considerations reflect evidence strength and typical selection criteria used in studies:

Selection for permanent ONS: Patient selection in most studies required a positive response to a temporary trial (typically ≥50% reduction in pain) before permanent implantation.≥50% pain reduction on trial

Used to select candidates in multiple studies

Efficacy evidence: Some modalities (REN, eTNS, tONS, PENS, TENS) have RCT evidence suggesting benefit for acute or preventive migraine; invasive ONS shows variable positive effects in selected patients for chronic migraine but evidence quality is low to very low, particularly for cluster headache.evidence quality: low to very low

Multiple systematic reviews and HTAs concluded benefit is possible but limited by small trials and short follow-up

Safety/complications: Invasive ONS and similar implants carry risks such as lead migration, infection, hardware malfunction, and need for revision or removal; infection rates requiring removal reported up to 27% in cluster headache series.

inv-11: Coverage-related guideline positions and conditions

Guideline-based stances and conditions for consideration of neuromodulation/interventional procedures:

ONS for occipital neuralgia: Congress of Neurological Surgeons: Clinicians may use occipital nerve stimulation (ONS) as a treatment option for medically refractory occipital neuralgia (Level III).Level III evidence

Evidence from case series and limited studies; small populations and short follow-up noted

NICE conditional use: NICE: transcutaneous SON stimulation for acute migraine may be used only with special arrangements for clinical governance, consent, and audit or research; prevention use only in context of research. ONS and SPG stimulation recommended only with special arrangements due to limited long-term evidence and risk of complications.use with governance/research

NICE encourages further research and data collection

VA/DoD stance:

Surgical and ablative procedures specifically listed as unproven and not medically necessary for diagnosing or treating occipital neuralgia or headaches are excluded per this policy. Examples include injection-based greater occipital nerve blocks (when claimed as a durable therapy rather than short-term diagnostic/therapeutic use), neurostimulation or electrical stimulation, occipital neurectomy, partial posterior intradural C1–C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1–C3 dorsal roots, and surgical decompression of the second cervical nerve root/ganglion or the greater occipital nerve. These interventions are listed as not medically necessary because the available evidence is insufficient to establish long-term efficacy for occipital neuralgia or headache indications.

Long-term, chronic preventive use of greater occipital nerve block (GONB) and surgical neuroplasty for occipital neuralgia is not supported by high‑quality evidence. Systematic reviews and technology assessments conclude GONB may provide short‑term relief but there is little to no evidence demonstrating sustained benefit as a preventive therapy, and larger, longer RCTs are needed. Similarly, neuroplasty and related surgical techniques for occipital neuralgia lack randomized controlled trials and sufficient peer‑reviewed data to establish safety and long‑term effectiveness; such procedures may be excluded or require strong clinical justification and specialty review.

Several surgical procedures and decompression/neurectomy techniques have insufficient evidence to establish safety or effectiveness for headache indications. The policy cites the lack of RCTs and inadequate published literature for procedures such as neuroplasty, occipital neurectomy, and decompression of supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal or greater occipital nerves. Because long‑term efficacy has not been established in well‑designed clinical trials, these procedures are treated as not supported by robust evidence.

Interventions for which adequate, well‑designed randomized controlled trials are lacking may be excluded or permitted only in the context of formal research or with strong supporting documentation. The available neurostimulation and electrical stimulation literature is limited by methodological flaws, small samples, and inconsistent designs; the policy notes that interventions lacking RCT evidence should generally require enrollment in clinical studies, special audit/governance arrangements, or detailed justification when considered outside research.

Several neuromodulation modalities are highlighted as having limited or inconclusive evidence and are therefore treated conditionally. The VA/DoD guidance summarized in the policy lists non‑invasive vagus nerve stimulation, supraorbital/external trigeminal stimulation, remote electrical neurostimulation (REN), external combined occipital and trigeminal approaches, rTMS, and tDCS among techniques with insufficient evidence to recommend for or against use; such modalities may be excluded or require strong justification, governance, or research arrangements.

Botulinum toxin A (BTX‑A) is not specifically FDA‑approved for cervicogenic headache or occipital neuralgia; thus its use for these diagnoses is off‑label. The policy explicitly notes that BTX‑A is not approved for treatment of cervicogenic headache or occipital neuralgia and should be considered off‑label in these contexts.

Member‑specific benefit plan terms may differ from the standard UnitedHealthcare policy. When plan documents conflict with this Medical Policy, the member specific benefit plan governs. Providers must check the member’s benefit plan and any applicable federal or state mandates before applying this policy to coverage decisions.

This policy references a range of interventions considered in the evaluation of occipital neuralgia and headache management, including injections (e.g., greater occipital nerve block), pulsed and thermal radiofrequency ablation (RFA/PRF), neurostimulation and peripheral nerve stimulation (implantable and external), occipital neurectomy, rhizotomy and posterior root procedures, surgical decompression and neuroplasty, sphenopalatine ganglion procedures, and other ablative or device‑based treatments. Coverage determinations vary by indication and evidence strength for each listed intervention.

Use of GONB for long‑term prevention of chronic migraine currently has little to no high‑quality evidence

Occipital neurectomy and nerve decompression procedures lack sufficient evidence of long‑term efficacy. The policy states that current evidence is insufficient to conclude these surgical approaches are effective for headaches, and long‑term outcomes have not been established in well‑designed clinical trials.

Routine or broad application of radiofrequency ablation (thermal or pulsed), pulsed radiofrequency, or neurostimulation for headache disorders is not supported when evidence is limited or inconsistent. The policy cites systematic reviews and retrospective studies that show variable and often low‑quality results; therefore routine use for headache types without robust supporting data is considered not medically necessary absent individualized justification, prior diagnostic block response, or specialist evaluation.

Occipital nerve stimulation (ONS) for chronic cluster headache has a very small and very low‑quality evidence base. Reviews and HTAs report uncertain clinical benefit and a relatively high rate of complications, including lead migration and infections that may require device removal; consequently, ONS for chronic cluster headache is considered of uncertain benefit and may be denied without strong supporting documentation or considered only under special arrangements.

Applicable Codes and Device Product Codes

Applicable CPT codes (group 1)CPT

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments.
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 11
1/2

Applicable CPT codes (group 2)CPT

64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint.
64634	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure).
64722	Decompression; unspecified nerve(s) (specify).
64744	Transection or avulsion of; greater occipital nerve.
64771	Transection or avulsion of other cranial nerve, extradural.
64999	Unlisted procedure, nervous system.

Applicable HCPCS codesHCPCS

A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

Applicable ICD-10 codesICD-10

C76.0	Malignant neoplasm of head, face and neck.
G89.3	Neoplasm related pain (acute) (chronic).

RFA device product codes (FDA)mixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Electrical stimulation device product codes (FDA)mixed

GZF	FDA product code for certain electrical stimulation devices
GZB	FDA product code for certain electrical stimulation devices
PCC	FDA product code for certain electrical stimulation devices

Device clearance/De Novo referencemixed

K203181

FDA PMN ID for Nerivio Migra remote electrical neuromodulator

MIDAS score — threshold and categories

MIDAS score threshold>= 6 indicates at least mild disability and prompts discussion with provider

MIDAS score categories0-5 = Little or no disability; 6-10 = Mild; 11-20 = Moderate; 21+ = Severe

MIDAS purposeQuestionnaire summing days from Q1-5 to measure impact of headaches on daily functioning

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization
Prior Authorization Required
Prior authorization may be required for the listed codes. Verify and obtain PA per the member-specific benefit plan and payer rules before scheduling services.
Prior authorization requirements apply per Colorado Rocky Mountain Health Plans rules and the member-specific benefit plan
PA may be required for diagnostic, therapeutic, and implantation procedures including GONB, RFA/PRF, neurostimulation trials and permanent implants

Step Therapy
Prior Authorization for Chronic Preventive Use
When greater occipital nerve blocks (GONB) or other interventions are used for chronic preventive therapy, PA may require documentation of inadequate response or intolerance to guideline-directed standard preventive medications and therapies.
Document failure, contraindication, or intolerance to standard preventive pharmacologic treatments before authorizing chronic preventive GONB
Consider step therapy: require trial of appropriate migraine-specific medications and behavioral therapies prior to authorization for chronic preventive interventional use

Required Conservative Therapy and Trial Requirements

inv-73: Trial of conservative medical therapy recommended prior to procedural interventions

Trial of conservative medical therapy recommended prior to procedural interventions

Initial conservative therapy: Before considering injections, ablation, neurostimulation, or surgery, document an adequate trial of conservative medical therapy (e.g., oral analgesics, antiinflammatory agents, and guideline-directed preventive medications) with insufficient benefit or intolerance.

Conservative measures are described as initial treatments; injections and procedural therapies are considered when medications fail or are not tolerated.

inv-74: Document inadequate response or intolerance to standard preventive therapies for chronic use

Document inadequate response or intolerance to standard preventive therapies for chronic use

Failed preventive therapy documentation: For chronic preventive use (e.g., repeat GONB or neuromodulation for prevention), document inadequate response or intolerance to guideline-directed standard preventive therapies before authorization.

Treatment Frequency and Repeat Procedure Considerations

GONB — trial frequency protocols

Typical trial protocolProtocols in trials varied; examples include once-weekly GONB for 3 weeks then monthly repeat if clinical response

Frequency used in RCTsSome randomized studies administered GONB weekly for up to 4 weeks with follow-up over months

Repeat dosing rationaleRepeat monthly injections were used in studies when patients reported decreased duration, severity, or frequency of headaches

C2 DRG pulsed RFA — follow-up and repeat procedure notes

Follow-up and repeat proceduresStudies report C2 DRG pulsed RFA performed for recurrence after initial block with follow-up; repeat procedures considered contingent on recurrence and response

Outcome timing

Imaging Guidance and Pre-procedure Imaging

Billing Rule
Include imaging when CPT/technique requires guidance (fluoroscopy/CT)
When CPT descriptions or procedural technique indicate imaging guidance (e.g., codes such as 64633/64634 or 64596), imaging (fluoroscopy, CT) is required per the procedure; include imaging documentation in the request.
CPT descriptors note imaging guidance; ASPN and procedural guidance recommend imaging for certain RFN and electrode placements.

Billing Rule
Document imaging guidance used for GONB (optional/technique-dependent)
For GONB, imaging guidance is optional and technique-dependent (e.g., ultrasound used in trials); document technique and guidance used when requesting authorization if imaging was performed.
Elsayed et al. used ultrasound-guided proximal/distal GONB; documentation of US guidance and technique is appropriate.

Procedures and Uses Not Covered

Radiofrequency ablation (thermal or pulsed) for occipital neuralgia or headache is identified among procedures considered not covered or unproven in this policy. Similarly, neurostimulation or electrical stimulation for occipital neuralgia/headache is listed as unsupported by sufficient evidence and may be treated as not covered for these indications. Neuroplasty for occipital neuralgia also lacks randomized trial evidence and is noted as not covered due to unestablished safety and effectiveness.

The policy reiterates that radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is considered unproven and not medically necessary for those indications. Likewise, neurostimulation or electrical stimulation procedures for occipital neuralgia/headache are flagged as having insufficient evidence to support routine coverage.

Radiofrequency ablation (thermal or pulsed) and related denervation procedures for occipital neuralgia/headache are repeatedly listed as unproven across the policy; neurostimulation and electrical stimulation for these diagnoses are similarly identified as lacking adequate evidence and may not be covered.

Neuroplasty for occipital neuralgia is specifically noted as lacking randomized controlled trial evidence; therefore safety and effectiveness have not been established and the procedure is not covered as an established therapy for ON.

The policy repeats that radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is considered unproven and not medically necessary for these indications, and therefore generally not covered.

Radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is identified as an unproven intervention and is not supported as covered for these diagnoses.

Clinical Background and Evidence Summary

Cervicogenic headache and occipital neuralgia are described as headache disorders arising from pathology of the cervical spine and occipital nerves (for example nerve impingement or entrapment). Diagnosis uses accepted criteria (IHS/Cervicogenic Headache International Study Group), and treatments range from conservative medical therapy to injections, ablation, neurostimulation, and surgical options. The policy’s background emphasizes that these conditions are neck‑related or occipital‑nerve mediated sources of head pain and that diagnostic clarity is important for selecting appropriate interventions.

Definitions and Outcome Measures

Cervicogenic Headache — definition

DefinitionReferred pain perceived in the head from a source in the neck due to disorders of the cervical spine and its components

Diagnostic contextDiagnosis uses IHS and Cervicogenic Headache International Study Group criteria (clinical documentation should support these criteria)

Common causesMay arise from bony, disc, and/or soft tissue elements of the cervical spine

MIDAS — description and categories

What MIDAS measuresMigraine Disability Assessment Test (MIDAS) measures impact of headaches by summing days from items 1-5

Score interpretation0-5 little/no disability; 6-10 mild; 11-20 moderate; 21+ severe

Policy Revision History

2026-01-01template_updateLatest

Created shared policy version to support application to Oxford plan membership and archived prior policy versions 2025T0080QQ and PAIN 018.38.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

Policy CodePolicy 2026T0080RR

Change TypeTemplate update / archival of prior versions

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

Definite positive response (eg ≥50%) to prior block predicts better outcome

Lee et al. reported higher success when prior C2 DRG block response present.

Device/intervention selection: Selection among RFA/PRF, peripheral nerve stimulation, occipital nerve stimulation, cervical SCS, REN, or other neuromodulation should be individualized based on diagnosis, prior response to blocks/trials, and device-specific evidence of benefit.

Evidence quality variable; REN has RCT support for prevention, while many implantable devices have low-quality evidence and risk of complications.

complication rates variable (up to 27% reported)

Weigh risks when considering implantation

VA/DoD: insufficient evidence to recommend for or against forms of neuromodulation for migraine treatment/prevention; insufficient evidence for GONB to prevent chronic migraine.

insufficient evidence

Guideline suggests no firm recommendation

Documentation Required
Diagnostic Block Response for Authorization
Positive response to a diagnostic occipital nerve block is commonly required to support authorization for subsequent interventions (e.g., RFA, PRF, neurostimulation). Documentation should show the magnitude and duration of relief.
Diagnostic block response typically defined as ≥50% pain relief (document percent reduction and time interval)
Include date of block, agent used, procedural notes, and duration of relief (baseline and post-block measures)

Prior Authorization
Prior Authorization for Permanent Implantation
Permanent neurostimulator implantation generally requires prior authorization and evidence of a successful temporary trial. PA should include documentation of prior conservative therapies and a positive trial response.
Evidence of a successful temporary trial (commonly ≥50% reduction in pain or other pre-specified responder definition) must be submitted
Document prior conservative and less invasive interventional attempts, indication, and rationale for permanent implant

Note
Device Regulatory Status (Informational)
Device regulatory status is informational: procedures are not regulated as devices but the instruments used are subject to FDA 510(k) clearance or other FDA processes. Cite device clearances where relevant.
RFA devices: FDA 510(k) cleared radiofrequency lesion generators/probes (product codes GXD, GXI)
Electrical stimulation devices: numerous FDA 510(k) listings; Nerivio Migra cleared via De Novo and subsequent 510(k) expansions

Prior Authorization
Verify Prior Authorization and Plan Rules
Verify prior authorization requirements and plan rules for the individual member before applying this policy. Member-specific benefit plans and any applicable federal/state mandates govern coverage.
Check Colorado Rocky Mountain Health Plans prior authorization portals and medical necessity submission requirements
When applicable, consider Medicare NCD/LCD guidance for Medicare Advantage members

Denial Risk
Denial Risk for Unproven Procedures
Procedures or therapies described in the policy that lack sufficient high-quality evidence may be denied as unproven or not medically necessary. Providers should be aware of denial risk for such interventions.
Examples at higher denial risk: occipital neurectomy, neurostimulation for certain indications without supportive evidence, neuroplasty, surgical decompression for occipital nerve
Lack of RCTs or consistent outcomes increases risk of noncoverage

Denial Risk
Evidence Limitations May Trigger Denial
Evidence limitations and heterogeneity in study designs may trigger additional documentation requests or denials. Lack of high-quality RCTs, inconsistent outcomes, and short follow-up are common concerns.
Insufficient or low-quality evidence for chronic use of some interventions may require stepwise therapy trials prior to approval
Prepare to submit supporting literature, trial data, and rationale when evidence is limited

Documentation Required
Governance, Consent, and Research Arrangements
Some procedures and devices should be used only with special arrangements for clinical governance, informed consent, audit, or within research contexts per guidance (e.g., NICE). Ensure organizational oversight when pursuing such interventions.
Inform clinical governance leads and obtain documented shared decision-making and written patient information when required
Collect and audit outcomes; consider participation in approved research or registry when evidence is inadequate

Documentation Required
Clinical Documentation and Diagnostic Criteria
Clinical documentation must support the diagnosis using accepted criteria (e.g., International Headache Society, Cervicogenic Headache International Study Group) and demonstrate prior conservative therapy attempts.
Include diagnostic criteria met, symptom history, neurologic exam, and relevant imaging when indicated (MRI/CT to exclude other etiologies)
Document prior conservative therapies (medications, physical therapy, behavioral therapy) and responses

Documentation Required
Document Baseline and Short-Term Outcomes
Document baseline and short-term outcomes to support medical necessity. Submit objective pre-procedure baselines and follow-up outcome measures showing benefit.
Baseline measures: headache frequency, intensity (e.g., VAS), MIDAS or MSQ scores, medication use
Short-term outcomes: percent pain reduction, headache-day reduction, functional scores at 1–8 weeks post-intervention

Documentation Required
Required Clinical Documentation to Support Intervention
Required clinical documentation to support interventions should include prior conservative therapy attempts, diagnostic/therapeutic block details, physical exam findings, and neurologist/pain specialist evaluations when applicable.
List of prior conservative treatments tried, durations, and reasons for discontinuation
Diagnostic block procedural report (agent, dose, technique), documented percent relief and duration, imaging guidance used

Documentation Required
Trial Response Documentation
Trial response documentation is commonly required for selection of candidates for permanent neurostimulation or more invasive procedures. Show the trial parameters and objective response.
Specify trial type (temporary ONS/SONS), duration of trial, stimulation settings, and patient-reported outcomes
Define responder threshold used (commonly ≥50% pain reduction) and provide follow-up notes documenting sustained benefit

Documentation Required
Required Supporting Documentation
Required supporting documentation for authorization of implants and interventions includes evidence of positive response to diagnostic or temporary stimulation trials and demonstration of prior less-invasive therapy failure.
Positive diagnostic block or temporary stimulation trial documentation (percent relief, duration)
Clinical rationale for escalation to implantable device and records of multidisciplinary evaluation when available

Step Therapy
Conservative and Stepwise Care Expectations
Follow conservative therapy and stepwise care expectations: try guideline-directed medical management and less-invasive interventional options before more invasive procedures. Use neuromodulation after inadequate response to medications and less-invasive therapies.
Conservative therapies include medications (acute and preventive), physical therapy, behavioral therapies, and targeted injections (e.g., diagnostic GONB)
Consider pulsed RFA or repeated GONB before surgical options; require documented failure of these approaches prior to surgery

Prior Authorization
Conservative Therapy Before RFA/PRF and Surgery
Conservative therapies should precede RFA/PRF and surgical procedures. Prior diagnostic/therapeutic nerve blocks are recommended to identify candidates likely to benefit.
Require documented inadequate response to conservative care prior to RFA/PRF
Diagnostic blocks showing clinically meaningful relief support proceeding to RFA/PRF

Note
Use of External Utilization Tools
Use of external utilization tools (e.g., InterQual®) and plan-specific criteria may be applied in administering benefits. Check payer-specific tools for step therapy and medical necessity algorithms.
Colorado Rocky Mountain Health Plans may apply external criteria or proprietary UM tools to support coverage decisions
Ensure submitted documentation aligns with any referenced external tool criteria to avoid delays

Hayes and other reviews recommend requiring failure of or intolerance to standard preventive therapies for chronic preventive indications.

inv-75: Document prior conservative management and response to diagnostic blocks (e.g., GONB, C2 DRG block)

Document prior conservative management and response to diagnostic blocks (e.g., GONB, C2 DRG block).

Prior conservative and diagnostic block documentation: Document prior conservative management attempts and the results of diagnostic/therapeutic nerve blocks (for example, GONB or C2 DRG block) including degree and duration of symptom relief.

Studies typically required failure of conservative treatments and often prior interventional trials before proceeding to RFA or surgery.

inv-76: Failed adequate trials of conservative and preventive medications; for implantable devices, failed noninvasive options and positive temporary trial

Failed adequate trials of conservative and preventive medications; for implantable devices, failed noninvasive options and positive temporary trial

Medication and noninvasive trial failure: Document failed adequate trials of conservative pharmacologic therapies and noninvasive neuromodulatory options prior to consideration of implantable devices.

AHS and other guidance suggest neuromodulation be offered after inadequate response to migraine-specific medications.

Positive temporary trial for implants: For permanent implantable neurostimulation, document a successful temporary trial (commonly defined as ≥50% reduction in pain or headache frequency) before implantation.≥50% reduction commonly used in trials

Hayes and other HTAs selected patients for implantation based on trial response.

inv-77: Failure of appropriate pharmacologic and less invasive therapies typically required before device implantation

Failure of appropriate pharmacologic and less invasive therapies typically required before device implantation.

Specialty-guided stepwise care: Device implantation (e.g., ONS, peripheral nerve stimulators, SCS) is generally reserved for patients who have failed appropriate pharmacologic and less invasive interventional therapies and who have been evaluated by specialists in headache or pain medicine.

AHS and AAPM guidance support offering neuromodulation after inadequate response to medications and suggest specialist involvement.

inv-78: Trial of standard medical therapy prior to invasive/interventional procedures

Trial of standard medical therapy prior to invasive/interventional procedures

Standard therapy before invasive options: Ensure a documented trial of standard medical therapies for migraine (acute and preventive) before pursuing invasive procedures; invasive treatments are generally reserved for refractory patients.

NICE states that usual treatment options are medical therapies and invasive treatments are reserved for individuals refractory to medical therapy.

Success often assessed at 6 months (e.g., ≥50% pain relief at 6 months reported in retrospective series)

Diagnostic block concordanceDefinite positive response to prior C2 DRG block (≥50% relief) associated with better outcomes after pulsed RFA

Frequency limits — general statement

No explicit frequency limitsThe policy section does not specify formal frequency limits; studies typically describe single or limited treatments with follow-up

Evidence on repeat sessionsSome reports document pain relief lasting months and describe repeat sessions in those with recurrence, but consistent interval guidance is not provided

ASPN guidanceASPN notes several studies documented six months of pain relief and states further studies are needed to recommend repeat RFN sessions

Billing Rule
Report fluoroscopy or ultrasound guidance for GONB, C2 DRG block, RFA
Procedures such as GONB, C2 DRG block, and RFA commonly use fluoroscopy or ultrasound guidance; when performed with imaging, include imaging modality and procedure notes in documentation.
Studies and procedural descriptions reference fluoroscopy or US guidance for needle placement and target confirmation.

Billing Rule
Document CT- or US-guidance when used for PRF/blocks
Some PRF procedures and nerve blocks in the literature were performed with CT or ultrasound guidance (for example CT-guided SPG PRFT or US-guided percutaneous PRF); include the imaging modality used in clinical notes.
Study reports describe CT- or US-guided PRF and blocks; document imaging technique used for reproducibility and authorization review.

Documentation Required
Provide MRI/CT to rule out other etiologies before occipital RFN
Before occipital radiofrequency neurotomy (RFN), MRI and/or CT imaging is recommended to rule out other etiologies; include imaging reports when available as part of the authorization package.
ASPN guidance recommends MRI/CT to exclude alternative causes prior to RFN though imaging is not diagnostic for occipital neuralgia.

Documentation Required
Document conditional neuroimaging decisions for initial cluster headache evaluation
For initial evaluation of cluster headache, neuroimaging is conditional—discuss need for imaging with a specialist and document the decision-making if imaging was or was not obtained.
NICE advises discussing neuroimaging need for first cluster headache episodes with a GP with special interest or neurologist.

Thermal or pulsed radiofrequency ablation of occipital nerves or related targets for occipital neuralgia/headache is treated as unproven in this policy and may be denied when billed for these indications.

Radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is repeatedly listed among procedures considered not medically necessary due to insufficient evidence.

The policy states radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is unproven and not covered as an established therapy for these indications.

Radiofrequency ablation (thermal or pulsed) for occipital neuralgia/headache is listed as unproven in multiple sections and therefore is generally not covered for these diagnoses.

Action thresholdIf MIDAS score >= 6, discussion with a provider is necessary

Greater occipital nerve block (GONB) — definition

DefinitionInjection of local anesthetic with or without corticosteroid at occipital trigger sites to reduce headache pain and frequency

UsesEmployed as diagnostic and therapeutic injection to identify occipital-mediated headache and as comparator/adjunct to RFA or surgery

Evidence noteSystematic reviews report short-term reductions in pain intensity and headache frequency, but long-term preventive benefit is uncertain

Neuroplasty (for occipital neuralgia) — definition and evidence

DefinitionNeuroplasty for occipital neuralgia refers to surgical/destructive or reparative procedures evaluated without randomized controlled trial evidence

Evidence noteLiterature is insufficient to establish safety or effectiveness; no RCTs identified in reviews

Migraine Headache Index (MHI) — outcome metric

DefinitionMigraine Headache Index (MHI) is a composite score derived by multiplying migraine severity, frequency, and duration

UseUsed as an outcome metric in surgical migraine studies and meta-analyses reporting changes in MHI

GONB — diagnostic and therapeutic use

Diagnostic and therapeutic roleGONB is used both to identify occipital-mediated headache and as a comparator or adjunct to RFA or surgery

Short-term effectSystematic reviews found reductions in pain severity and headache frequency at 1–6 week follow-ups

Technique variabilityStudies vary in technique, image guidance and use of corticosteroid; evidence quality is often limited

Pulsed radiofrequency (PRF / PRFT) — definition and intent

DefinitionPulsed radiofrequency (PRF/PRFT) is a non-ablative radiofrequency technique applied percutaneously to neural targets intended to provide neuromodulation and pain reduction

IntentDesigned to modulate pain signals with less tissue destruction than continuous thermal RFA

Evidence noteSystematic reviews and trials report short- to mid-term analgesic benefits for some headache types, but optimal targets and settings remain unclear

Remote electrical neuromodulation (REN) — definition and trial note

DefinitionRemote electrical neuromodulation (REN) is a noninvasive device-based neuromodulation technique evaluated for migraine prevention

Trial result noteRandomized trial (Tepper et al.) showed REN produced significant reductions in migraine days and higher rates of ≥50% reduction in moderate/severe headache days versus sham

Positive temporary trial — definition and role

DefinitionPositive temporary trial: a temporary stimulation trial typically defined in studies as ≥50% reduction in pain lasting for a few weeks used to select patients for permanent implants

Role in authorizationDocumentation of a positive trial (commonly ≥50% pain reduction) is frequently required before permanent ONS implantation

Transcutaneous electrical stimulation of the SON / eTNS — definition

DefinitionTranscutaneous electrical stimulation of the supraorbital nerve (SON) / eTNS: external stimulation through the skin using a small battery-operated device (headband and adhesive electrode) applied to the forehead to stimulate SON branches

Use patternApplied daily for acute treatment (1–2 hours) or for short prevention sessions (about 20 minutes) per NICE description

Botulinum toxin A (BTX-A) — approval note / off-label

Regulatory/approval noteBotulinum toxin A (BTX-A) is an FDA-approved neurolytic agent for some conditions but is not specifically approved for cervicogenic headache or occipital neuralgia (off-label use for these diagnoses)

Clinical contextBTX-A has recognized indications for chronic migraine prevention (per other guidance) but use for ON/cervicogenic headache is off-label

Occipital nerve stimulation (ONS) — definition and evidence context

DefinitionOccipital nerve stimulation (ONS) is an implantable neuromodulation technique delivering electrical stimulation to occipital nerves for chronic headache disorders

Evidence contextSystematic reviews and HTAs report variable positive treatment effects in selected patients, selection often required a positive temporary trial, and complications (lead issues, infection) are reported

Outcome variabilityReported overall response rates across indications vary widely (e.g., 35.7–100%) and evidence quality is generally low to very low